Technology

Adaptive Clinical Systems Enters Into Data Interoperability Partnership with Trial Interactive

Published

2 years ago

September 16, 2024

Adaptive Clinical Systems is pleased to announce that it has entered a partnership on data interoperability with TransPerfect’s Trial Interactive. Clinical sponsors and CROs leveraging the Trial Interactive eClinical platform benefit from an additional layer of interoperability via streamlined data aggregation from disparate sources by using the Adaptive eClinical Bus.

SARASOTA, Fla., Sept. 16, 2024 /PRNewswire-PRWeb/ — Adaptive Clinical Systems is pleased to announce that it has entered a partnership on data interoperability with TransPerfect’s Trial Interactive. Clinical sponsors and CROs leveraging the Trial Interactive eClinical platform benefit from an additional layer of interoperability via streamlined data aggregation from disparate sources.

“As our industry trends towards complex studies, sponsors find themselves in a multi-CRO environment with disparate systems in need of interoperability,” said Sina Adibi, CEO, Adaptive Clinical Systems. “This partnership enables sponsors to benefit from a robust interoperable eClinical ecosystem.”

The Adaptive eClinical Bus® and DataVIEW® solutions support augmentations that expand real-time patient monitoring by connecting more data sources, while offering additional options for reporting and visualization. Sponsors leveraging a diverse infrastructure of eClinical technologies from different providers and platforms gain a simplified means to securely and seamlessly exchange data and documents between systems.

Sponsors who take advantage of this partnership also gain access to both the Adaptive Clinical and Trial Interactive platform ecosystems. This interconnectivity creates a powerful extensibility augmentation of Trial Interactive’s seamless suite of solutions (including eTMF, CTMS, Study Start-Up, eISF, LMS, eFeasibility, and more) through a full library of third-party interconnects. Sponsors can easily exchange data with any tool to enable holistic data management. For study teams planning implementations involving systems from various providers, this partnership will reduce and/or eliminate the need for custom API integrations, helping to improve timelines and reduce cost (especially when starting a new study).

“Sponsors need the flexibility to enable the eClinical infrastructure that best meets their requirements,” said Michael Smyth, Division President, TransPerfect Life Sciences. “This partnership offers study teams and IT even more options for a seamless and right-fit setup.”

“As our industry trends towards more complex studies, even small to mid-size sponsors find themselves in a multi-CRO environment with disparate systems in need of interoperability,” said Sina Adibi, CEO and President, Adaptive Clinical Systems. “This partnership enables sponsors of any size to benefit from a robust interoperable eClinical ecosystem.”

About Trial Interactive

TransPerfect’s Trial Interactive is an industry leader in practical e-clinical innovation that simplifies and automates clinical processes for sponsors, CROs, and sites around the world. The 21 CFR part 11 compliant and HITRUST certified platform delivers an author-to-archive collaboration experience with solutions for clinical document management, site selection, site activation, e-learning, compliance training, quality, and more with seamless solution interoperability and indexing to the eTMF. Trial Interactive is consistently selected by clinical professionals for providing the most comprehensive yet intuitive experience with the most complete offering of technology and expert TMF services. Trial Interactive helps study teams streamline their operations by cutting unnecessary expenses, expediting timelines, reducing compliance risks, and improving operational excellence. For more information on Trial Interactive, please contact info@trialinteractive.com or +1 212.400.8848, or visit www.trialinteractive.com.

About TransPerfect Life Sciences

TransPerfect Life Sciences specializes in supporting the global development and commercialization of drugs, treatments, and devices designed to improve and save lives. Our comprehensive solutions include clinical trial management technology and services (TMF services, eTMF, CTMS, regulated content management, etc.), pharmacovigilance and safety solutions, translation and language services, and call center support. With offices in over 140 cities worldwide, TransPerfect is the ideal partner to simplify your path from lab to launch by driving quality, mitigating compliance risk, and enhancing patient engagement. For more information, please visit our website at https://lifesciences.transperfect.com/

About Adaptive Clinical Systems

Adaptive Clinical Systems, a global life sciences technology company, provides the leading data integration platform for clinical research. With the Adaptive eClinical Bus® and Adaptive DataVIEW®, see how your clinical trial data is transformed with data in motion. Adaptive Clinical’s solutions enable data streams across all study partners and eClinical eSources. Whether your challenge is data visualization, API integrations or data integration, our solutions help remove data islands and silos. We make your data actionable faster. For more information, please see Adaptive Clinical Systems website: www.adaptive-clinical.com.

Media Contact
Mitch Collins, Adaptive Clinical Systems, 1 856-473-4370, mitch.collins@adaptive-clinical.com, www.adaptive-clinical.com

View original content to download multimedia:https://www.prweb.com/releases/adaptive-clinical-systems-enters-into-data-interoperability-partnership-with-trial-interactive-302245389.html

SOURCE Adaptive Clinical Systems

Technology

Datavault AI Founder Nathaniel Bradley Sues Board

Published

2 minutes ago

November 7, 2026

WILMINGTON, Del., Nov. 6, 2026 /PRNewswire/ — Lawsuit Alleges Chairman and CFO Brett Moyer Engineered a Weekend Lockout While Keeping a $90–$100 Million Financing Offer From Independent Directors

Datavault AI Founder Nathaniel Bradley Sues Board

Nathaniel Bradley, the founder whose technology became Nasdaq-listed Datavault AI Inc. (NASDAQ: DVLT), today filed a lawsuit in the Delaware Court of Chancery asking the court to declare his contested ouster as CEO void and restore him to office. The complaint alleges that Board Chairman and CFO Brett Moyer “suspended” Bradley without a Board vote, cut off his email, and then rushed through a defective Sunday meeting, all while a $90–$100 million financing lifeline sat on the table.

On October 30, two days after Bradley asked the Board to consider removing Moyer as CFO, Moyer “suspended” Bradley on his own perceived authority. According to the complaint, no Board meeting was held and no written consent was circulated. This was done despite Datavault’s own Bylaws, which give only the full Board the power to remove officers.

The lawsuit further alleges that Moyer and certain unnamed directors shut Bradley out one day after he brought the company a $90–$100 million funding offer that could have substantially improved its financial position. Rather than present the offer, Moyer “suppressed, withheld and concealed” it from the company’s independent directors.

Last night, Bradley released the following statement:

“While I remain confident in Datavault AI’s technology, product offerings, and patent-protected innovations, I strongly dispute the legal validity of the Board’s decision to remove me as President and Chief Executive Officer.

“During my tenure, we increased revenue by more than 1,300% in my first year, alongside record trading volumes, and built the foundation for continued growth. We assembled a portfolio of more than

100 patents and pending applications, including newly issued U.S. patents in data valuation, tokenization, and wireless audio. We launched the Information Data Exchange, NIL Vault, and American Political Exchange, and signed licensing and tokenization agreements that bring real-world assets, from carbon credits to gold, copper, and geothermal energy, onto our platforms. We also completed strategic acquisitions, including API Media Innovations, that expanded our reach into digital twins, sports, and live events. We broadened our strategic partnership network, including with IBM,

ServiceNow, and the Department of Energy, and recruited industry-leading talent to the Datavault cause.

“Innovators are often targeted, and I intend to protect my rights and the interests of the Company and its shareholders. I believe the Board’s action jeopardizes the Company’s ability to realize its full potential.”

Jacob Frenkel, Bradley’s lead counsel and a former SEC enforcement lawyer and federal prosecutor, said:

“The company’s groundbreaking and cutting-edge technologies are a function of Mr. Bradley’s brilliance and vision. As a corporate leader, Mr. Bradley has a long-standing commitment to best practices in corporate governance.”

Mr. Bradley puts his investors first. When you’re out building and innovating and those you think you can trust decide to stage a corporate coup, the only place for relief is in court. Mr. Bradley will continue to fight for the shareholders and against those who put their own interests ahead of the company’s stakeholders.”

Read the full complaint here.

About Nathaniel Bradley:

Nathaniel Bradley is an inventor and technology executive who holds more than 70 patents. He founded and invented AudioEye, founded Intellectual Property Network Inc., and served as CTO of Marathon Patent Group (now Marathon Digital Holdings). In 2021, he founded Data Vault Holdings, whose assets were acquired in December 2024 by WiSA Technologies, the company that became Datavault AI. As CEO, he led the company through partnerships with IBM, Dolby Laboratories, and NYIAX, as well as the acquisition of CompuSystems assets.

View original content:https://www.prnewswire.com/news-releases/datavault-ai-founder-nathaniel-bradley-sues-board-302932495.html

SOURCE Datavault AI Inc

Technology

County of Sussex, New Jersey Notice of Data Privacy Incident

Published

3 minutes ago

November 7, 2026

NEWTON, N.J., Nov. 6, 2026 /PRNewswire/ — Sussex County Prosecutor’s Office (SCPO) experienced a data privacy event that involved personal information.

On or about August 10, 2026, SCPO received alerts of a disruption to its computer network. Upon this identification, it launched an immediate investigation and engaged outside cybersecurity specialists to assist. The investigation determined that someone accessed its network without authorization between July 15, 2026, and July 22, 2026, and that certain files containing personal information were accessed and may have been taken. That information includes people’s first and last name, Social Security number, and driver’s license or State-issued identification card number. The SCPO has reported the incident to state and federal law enforcement, the New Jersey Cybersecurity and Communications Integration Cell (NJCCIC), and the Office of Attorney General. For more information on this incident, people may contact the call center at (888) 269-1448, Monday through Friday, 9:00 a.m. to 9:00 p.m. EST for further assistance.

Lauren Stinger, Esq.
Lauren.stinger@kennedyslaw.com
Associate Counsel

View original content:https://www.prnewswire.com/news-releases/county-of-sussex-new-jersey-notice-of-data-privacy-incident-302932369.html

SOURCE Kennedys CMK LLP

Technology

Light AI Announces Resignation of Director and Officer

Published

1 hour ago

November 7, 2026

VANCOUVER, BC, Nov. 6, 2026 /CNW/ — Light AI Inc. (“Light AI” or the “Company”) (CBOE CA: ALGO (FSE: OHC) (OTCQB: OHCFF), announces that Peter Whitehead has resigned as a director and the Chief Innovation Officer of the Company to pursue other opportunities. The Company would like to thank Mr. Whitehead for his contributions to the Company.

About Light AI Inc. (CBOE CA: ALGO / FSE: OHC / OTCQB: OHCFF)

Light AI Inc. is a healthcare technology company focused on developing artificial intelligence-powered SaMD solutions designed to support rapid, accessible clinical assessment at the point of care. The Company’s core technology, Light AI QuickScan™, is a device-agnostic software platform that applies proprietary artificial intelligence and machine learning algorithms to medical images. The QuickScan™ platform is designed to operate across compatible imaging and computing hardware, providing flexibility for integration into a range of healthcare devices, clinical workflows and care settings without dependence on a single proprietary hardware platform.

ON BEHALF OF THE COMPANY

“John R. Luna”
Chief Executive Officer

For more information, please contact the Company at investors@light.ai or visit https://light.ai/.

Website: https://light.ai/
LinkedIn: LinkedIn/company/Light AI
X (Formerly Twitter): @lightaihealth

SOURCE Light AI Inc.